7 active not recruiting, 7 terminated, 4 recruiting, 3 withdrawn. 22 Phase 1, 10 Phase 2, 1 Early Phase 1, 1 Phase 3.
Follow Bellicum Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) Fludarabine Phosphate, Cyclophosphamide, Cetuximab - Colorectal Cancer, Minimal Residual Disease | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2024-12-02 | 2026-08-04 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-09-16 |
| Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate - Solid Tumors | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2023-10-24 | 2026-10-06 |
| Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer iC9.GD2.CAR.IL-15 T Infusion - Lung Cancer, Small Cell Lung Carcinoma | Early Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 24 | 2023-06-21 | 2026-02-05 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors chimeric antigen receptor (CAR) T cell therapy - HER-2 Gene Amplification, HER2-positive Gastric Cancer | Phase 1 | Suspended | Bellicum Pharmaceuticals | 220 | 2020-12-07 | 2023-04-20 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903 - Graft Versus Host Disease, Hematological Malignancies | Phase 1 / Phase 2 | Terminated | Centre Hospitalier Universitaire de Besancon | 2 | 2019-04-10 | 2025-07-09 |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine - Neuroblastoma, Osteosarcoma | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 18 | 2019-02-19 | 2026-03-27 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant BPX-501 T cells, rimiducid - Hematologic Malignancy | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 15 | 2018-02-01 | 2022-07-12 |
| Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma BPX-701, Rimiducid - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 4 | 2017-04-14 | 2023-10-05 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Rimiducid, rivogenlecleucel - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2017-01-01 | 2023-09-26 |
| Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies BPX-501, AP1903 - Hematologic Malignancies | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-07-01 | 2020-10-05 | |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant BPX-501, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Bellicum Pharmaceuticals | 10 | 2016-07-01 | 2022-07-12 |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT rivogenlecleucel, Rimiducid - Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-05-01 | 2020-10-05 | |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab - Malignant Pleural Disease, Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 113 | 2015-05-01 | 2026-07-22 |
| Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases BPX-501 and Rimiducid - Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis | Phase 1 | Terminated | Bellicum Pharmaceuticals | 1 | 2015-02-01 | 2024-03-25 |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Active not recruiting | Bellicum Pharmaceuticals | 120 | 2014-04-01 | 2022-07-12 |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant BPX-501 T cells, Rimiducid - Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1 / Phase 2 | Terminated | Bellicum Pharmaceuticals | 187 | 2014-04-01 | 2023-09-29 |
Showing 20 of 27. Sign in to see all of them.
Myelodysplastic Syndromes (12) · Leukemia (9) · Hematologic Neoplasms (8) · Leukemia, Myeloid, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Lymphoma (5) · Lymphoma, Non-Hodgkin (4) · Primary Immunodeficiency Diseases (4) · Anemia, Aplastic (3) · Anemia, Diamond-Blackfan (3) · Anemia, Sickle Cell (3) · Cytopenia (3) · Fanconi Anemia (3) · Hemoglobinopathies (3) · Hodgkin Disease (3)
AP 1903 reagent (19) · Cyclophosphamide (9) · fludarabine (8) · fludarabine phosphate (7) · Alemtuzumab (1) · Automobiles (1) · Cell- and Tissue-Based Therapy (1) · Cetuximab (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Injections (1) · Melphalan (1) · Methylprednisolone (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1)
United States (22) · Italy (3) · France (1) · United Kingdom (1)
Ecaterina Dumbrava, M D (1) · Elizabeth Krakow (1) · George Hucks, MD (1) · Guru Sonpavde, MD (1) · Jared Weiss (1) · Jared Weiss, MD (1) · Lawrence Fong, MD (1) · Maria Pia Morelli, MD, PhD (1) · Matthew Foster, MD (1)
PMID 35045358, PMID 38321811, PMID 39897044
K12CA120780 (1), P30CA015704 (1), R01CA296807 (1)